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Abstract
Objective/Background: Lymphoma is seen as a highly treatable and curable malignancy with aggressive treatment
methods. Efﬁcacy is often limited by toxicity and many patients need alternative treatment strategies as they cannot
tolerate existing high cytotoxic approaches. Our aim is to compare BEAM [carmustine (BCNU), etoposide, cytarabine
(ARA-C, cytosine arabinoside), and melphalan] and mitoxantroneemelphalan (Mx-Mel) regimens utilized in our patients with a diagnosis of lymphoma who underwent autologous stem cell transplantation (ASCT), and to demonstrate
that the Mx-Mel regimen has similar but less toxic results than the BEAM regimen we have been using frequently as
standard conditioning regimen.
Methods: A total of 101 patients with lymphoma who underwent ASCT were included in our study. The BEAM regimen
included BCNU, etoposide, ARA-C, and melphalan. The Mx-Mel regimen included mitoxantrone and melphalan.
Results: Of 101 patients included in the study, 60 (59.4%) received BEAM and 41 (40.6%) received Mx-Mel (40.6%)
conditioning regimen. The median time to neutrophil engraftment was 10 (range: 9e20) days and 12 (range: 9e12) days
in the BEAM and Mx-Mel arms, respectively; it was statistically signiﬁcantly shorter in the BEAM arm ( p ¼ .001).
Conclusion: This study demonstrates that the Mx-Mel regimen has similar efﬁcacy and toxicity compared with the
BEAM regimen. Although time to neutrophil engraftment was shorter in the BEAM arm, it did not result as signiﬁcant
transplant-related complications between the two regimens. The Mx-Mel regimen is seen as a good alternative with low
toxicity and high efﬁcacy.
Keywords: Autologous stem cell transplantation, BEAM, Lymphoma, Mitoxantrone, Prognosis

1. Introduction

H

odgkin lymphoma (HL) represents about 11%
of all lymphomas [1]. This disease manifests
with a distribution with two peaks (young adults,
and patients who are 55 years old and older) [1,2].
With the advances in HL approaches, a very
important step has been made in the treatment of

patients diagnosed who are aged 60 years or
younger. Despite these optimistic results, 5e10% of
all cases are in the relapsed/refractory (R/R) group,
including patients who achieved complete remission (CR) after initial treatment [2].
Non-Hodgkin lymphoma (NHL) represents a
heterogeneous group of diseases, mostly of B-cell
origin. B-cell NHL is generally classiﬁed into two
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broad subsections: aggressive and indolent lymphomas. The most common subtypes of these lymphomas are diffuse large B-cell lymphoma and
follicular lymphoma [3]. NHL is seen as a highly
treatable and curable malignancy, speciﬁcally with
aggressive treatment methods. However, efﬁcacy is
often limited by toxicity and many patients need
alternative treatment strategies as they cannot
tolerate existing high cytotoxic approaches.
For both lymphoma subtypes in primary refractory disease, conventional salvage therapy in
patients with responding disease, despite lack of
CR, and followed by high-dose chemotherapy and
autologous stem cell transplantation (ASCT) is the
standard approach. Consolidation with ASCT after
salvage chemotherapy in patients with R/R NHL
can provide curative therapy [4]. An important
study based on ASCT, Philip et al. [5] compared
salvage therapy with ASCT in patients diagnosed
with high-grade B- and T-cell lymphomas. After 5
years of follow-up, the overall survival (OS) was
53% in the ASCT group and 32% in the salvage
therapy group ( p ¼ .038). In aggressive NHL,
frontline ASCT is also one of the topics discussed.
In the study by Schmitz et al. [6], which is one of
the basic ASCT studies dealing with the chemosensitive patient group in the ﬁrst relapse in HL, the
3-year progression-free survival (PFS) was 55% in
the ASCT arm versus 34% in the salvage therapy
arm. There was no signiﬁcant difference in terms of
OS. Although frontline consolidative ASCT is also
discussed in advanced stage patients in HL, it does
not provide an OS advantage [7].
The most widely used conditioning regimens in
patients with lymphoma are carmustine (BCNU),
etoposide, cytarabine (ARA-C), and melphalan
(BEAM); carmustine, etoposide, cytarabine, and
cyclophosphamide (BEAC) [8]; busulfan, cyclophosphamide, and etoposide (BUCYVP-16) [9];
busulfan, cyclophosphamide, etoposide (BuCyE)
[10]; mitoxantroneemelphalan (Mx-Mel) [11]; and
combination regimens with total body irradiation
[12]. Besides, there are such regimens similar to
BEAM as lomustine, etoposide, cytarabine, and
melphalan (LEAM) [13], in which lomustine is used
instead of BCNU, BeEAM [14], in which bendamustine is used, and FEAM [15], in which fotemustine is used. In the ASCT treatment process, the
main goal should be to achieve maximum effect
with low toxicity. We see that many studies are
performed for this purpose.
Our aim in this study is to compare BEAM and
Mx-Mel regimens used in our patients with a
diagnosis of NHL and HL who underwent ASCT,

and to show that the Mx-Mel regimen has similar
but less toxic results compared with the BEAM
regimen we have been using frequently as standard
conditioning regimen. There were several important
reasons in choosing the Mx-Mel regimen while
conducting our study. Our experience with Mitoxantrone is quite sufﬁcient due to the acute myeloid
leukemia induction therapies. The use of mitoxantrone as another anthracycline was also a suitable
option for all patients with lymphoma, as doxorubicin was preferred in the ﬁrst-line treatment regimens for both HL and NHL.

2. Materials and methods
2.1. Patients
A total of 101 patients who underwent ASCT with
the diagnosis of lymphoma were included in our
retrospective study in the Bone Marrow Transplantation Unit at Gaziantep University between
2014 and 2019. The patients were evaluated retrospectively; Mx-Mel or BEAM regimen was used
according to treating physician’s preference.
Patients who are at least 18 years old, have a
chemosensitive disease, and achieved at least partial
response with salvage therapy, ejection fraction of
55% and above, creatinine clearance of 60% and
above, adequate lung/liver functions, and Eastern
Cooperative Oncology Group (ECOG) performance
status 0e2 were included in the study. Patients with
central nervous system involvement, chemorefractory disease, and who received BEAM as
salvage therapy were excluded from our study. Responses to the initial induction chemotherapy,
salvage chemotherapy, and SCT were evaluated
according to the International Workshop Criteria
(Cheson Criteria) [16]. The Common Terminology
Criteria for Adverse Events (CTCAE 4.0) Toxicity
Scale is speciﬁcally used to rate the complications
caused by chemotherapy during the hospitalization
process of SCT. In all patients, the maximum recommended cumulative dose of anthracycline was
calculated and none of the patients received more
than the dose of anthracycline allowance. The study
was approved by the Toros University (Mersin,
Turkey) institutional review and local ethics committee. Ethical committee approval was received
(Approval date and number: 18.01.2019e1645) and
the patients and control patients gave informed
written consent before the beginning of the study.
The experimental procedures were based on the
Declaration of Helsinki and relevant institutional
regulations.
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Transplant procedure and conditioning regimen
The BEAM regimen included BCNU at 300 mg/m2
on Day e7, etoposide at 200 mg/m2 and ARA-C at
200 mg/m2 BID on Days e6 to e3, and melphalan at
140 mg/m2 on Day e2. The Mx-Mel regimen
included mitoxantrone 60 mg/m2 at Day e5 and
melphalan 180 mg/m2 at Day e2. The total dose of
mitoxantrone was given as three individually
divided doses with 1-hour intervals on the same
day. Collected CD34-positive cells were re-infused
on Day 0. The protocols of conditioning regimens
are summarized in Table 1.
Chemotherapy (cisplatin-based or gemcitabinebased therapy) and granulocyte colony-stimulating
factor (G-CSF; 5e10 mg/kg/day) or plerixafor plus GCSF (10 mg/kg/day) were used as a mobilization
process.
All patients received G-CSF 5 mg/kg from Day þ 5
of ASCT until neutrophil engraftment. All patients
received levoﬂoxacin at 500 mg/day, ﬂuconazole at
300 mg/day, and valacyclovir at 500 mg/day until
neutrophil engraftment. Tumor lysis syndrome
prophylaxis was applied from Day e7 to e1 with
allopurinol 300 mg/day. Packed red cell concentrates were given to maintain hemoglobin > 7.0 g/
dL. Platelet concentrates were given when platelet
count was < 10  109/L.
Neutrophil engraftment was deﬁned as the day of
absolute neutrophil count  0.5  109/L, while
platelet engraftment was deﬁned as the ﬁrst of 3
consecutive days that platelet count was  20  109/
L with no requirement for platelet transfusion.

3. There were no changes to transplant-related
supportive care, antimicrobial prophylaxis,
and/or growth factor support during that time
period.
3.1. Outcome evaluation
Transplant-related mortality (TRM) was deﬁned
as any death unrelated to relapse or progressive
disease during the ﬁrst 100 days after the transplant.
PFS was considered as the time from the date of
transplant to the beginning of the next treatment,
disease progression, relapse, death, or last follow-
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up. OS was deﬁned as the time from ASCT until
death or the date the patient was last known to be
alive. The cut-off date for survival analysis for all
patients was June 30, 2019.
3.2. Statistical analysis
The SPSS version 23 (SPSS Inc., Chicago, IL, USA)
was used for data analysis. KolmogoroveSmirnov
and ShapiroeWilk tests were used to analyze the
normal distribution of data. Those with normal distribution in numerical variables were summarized as
mean ± standard deviation, and those without
normal distribution were summarized as median
(minimumemaximum). Number and percentage
expressions were used for categorical variables. In
the analysis of categorical variables, chi-square test
was used. ManneWhitney U test was used for the
analysis of the differences between nonparametric
independent variables, and t test was used for the
analysis of parametric variables. Survival analysis
and graphics were performed by KaplaneMeier
analysis. Survival differences were analyzed by the
log-rank test. Survival-related ﬁndings were evaluated by univariate analysis, and risk factors that were
found to be signiﬁcant were analyzed using the
multivariate Cox regression model. In statistical
analysis, p < .05 was considered as signiﬁcant.

4. Results
Of 101 patients included in the study, 60 (59.4%)
received BEAM and 41 (40.6%) received Mx-Mel
conditioning regimen. In the BEAM arm, 34 (56.3%)
patients were diagnosed with NHL and 26 (43.3%)
with HL. In the Mx-Mel arm, 24 (58.5%) patients
were diagnosed with NHL and 17 (41.5%) with HL.
There was statistically no signiﬁcant difference in
disease distribution ( p ¼ .85). Hematopoietic stem
cell transplantation speciﬁc comorbidity indexes of
the patient subgroups were also calculated. In the
BEAM arm, median value was 2 (range: 0e8), while
in the Mx-Mel arm, it was 3 (range: 0e8). There was
statistically no signiﬁcant difference between the
two groups (Table 2).
There was statistically no signiﬁcant difference
between the two treatment subgroups in terms of

Table 1. Protocols of Conditioning Regimens.
BEAM protocol
BCNU (300 mg/m2)
Etoposid (200 mg/m2/day)
ARA-C (200 mg/ m2 BID)
Melphalan (140 mg/m2)

Mitoxantroneemelphalan protocol
(Day e7)
(Days e6, e5, e4, e3)
(Days e6, e5, e4, e3)
(Day e2)

Mitoxantrone (60 mg/m2)
Melphalan (180 mg/m2)

Note. BEAM ¼ BCNU, etoposide, ARA-C, and melphalan; BID ¼ twice daily.

(Day e5)
(Day e2)
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Table 2. Baseline Patient and Disease Characteristics.

Patients
Age, median (range)
Sex
Histologic subtype
Stage
Bulky disease
Bone marrow involvement
ECOG performance status

Disease status at transplant
HCT-CI, mean (range)

years
Male
Female
NHL
HL
IeII
IIIeIV
Yes
No
Yes
No
0
1
2
PR
CR

Total patients

BEAM

Mx-Mel

101
45 (18e69)
68
33
58
43
18
83
9
92
33
68

60
46 (18e69)
44 (73.3)
16 (26.7)
34 (56.3)
26 (43.3)
13 (21.7)
47 (78.3)
3 (5)
57 (95)
22 (36.7)
38 (62.3)
49 (81.7)
8 (13.3)
3 (5)
10 (16.7)
50 (82.3)
2 (0e8)

41
43 (18e69)
24 (58.5)
17 (41.5)
24 (58.5)
17 (41.5)
5 (12.2)
36 (87.8)
6 (14.6)
35 (85.4)
11 (26.8)
30 (72.2)
32 (78)
7 (17.1)
2 (4.9)
9 (22)
32 (78)
3 (0e8)

19
82
2 (0e8)

p
0.52
0.11
0.85
0.22
0.09
0.30
0.87

0.50
0.91

Note. Data are presented as n (%) unless otherwise indicated. BEAM ¼ BCNU, etoposide, ARA-C, and melphalan; CR ¼ complete
response; ECOG ¼ Eastern Cooperative Oncology Group; HCT-CI ¼ hematopoietic stem cell transplantation speciﬁc comorbidity index;
HL ¼ Hodgkin lymphoma; Mx-Mel ¼ mitoxantroneemelphalan; NHL ¼ non-Hodgkin lymphoma; PR ¼ partial response.

the stages of diagnosis, presence of bulky disease,
presence of bone marrow involvement, ECOG
scores, and treatment response at the time of
transplant of the patients included in the study ( p >
.05; Table 2).
There was statistically no signiﬁcant difference
between the mobilization regimes of the patients ( p
¼ .57). The median stem cell count was 9  106/kg in
both arms. Times to engraftment of the patients
were evaluated separately in both subgroups. The
median time to neutrophil engraftment was 10
(9e20) days and 12 (9e12) days in the BEAM and
Mx-Mel arms, respectively; it was statistically
signiﬁcantly shorter in the BEAM arm ( p ¼ .001).
There was statistically no signiﬁcant difference between the two groups in terms of platelet engraftment ( p > .05; Table 3).
When the adverse effect proﬁle was examined,
there was statistically no signiﬁcant difference between the two groups in terms of number of febrile
neutropenic attacks, mucositis, gastrointestinal,
renal, and hepatotoxicity. Febrile neutropenia attacks were analyzed by dividing into subgroups:
fever of unknown origin, proven infections (bacteremia, pneumonia, gastrointestinal infection, and
urinary infection). There was no statistical difference in subgroups between the two treatment arms
( p > .05; Table 3).
Considering the transplant-related 100-day mortality, it was seen that a total of three patients (two in
the BEAM arm and one in the Mx-Mel arm) were
exitus. There was statistically no signiﬁcant difference ( p ¼ .79; Table 4).

The distribution of 1-year OS and PFS was 96.6%
and e97.5% in the BEAM arm and 95% and e95.1%
in the Mx-Mel arm, respectively. The distribution of
5-year OS and PFS was 69% and e75% in the BEAM
arm and 61% and e74% in the Mx-Mel arm. There
was no statistically signiﬁcant difference between
the two subgroups ( p > .05). The median duration of
follow-up was 44 (range: 3e112) months and 14
(range: 3e62) months in the BEAM and Mx-Mel
arms, respectively. It was observed to be signiﬁcantly longer in the BEAM arm ( p < .001; Table 4).

5. Discussion
The results of this study contain important ﬁndings in terms of comparing BEAM and Mx-Mel
regimens and evaluating their efﬁcacy in the lymphoma group. It contains very valuable data as it is
based on single-center patients’ results.
It is possible to say that there are similar studies in
the literature which evaluate the effectiveness and
toxicity of the BEAM regimen. In one of the
important studies, Yeral et al. [17] retrospectively
evaluated multicenter data of ASCT patients. In the
study, in which the efﬁcacy and toxicities of BEAM
and Mx-Mel preparation regimens were discussed
in detail, the 3-year expected OS and PFS after
ASCT were 86.1% and 86.1% in the Mx-Mel group,
respectively, while in the BEAM group it was 91.3%
and 76.5%, respectively. Although febrile neutropenia attacks developed in 50% of the patients in
the Mx-Mel group, this rate was 91.1% in the BEAM
group. Grade II and higher hepatic, renal,
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Table 3. Transplant, Engraftment and Toxicity Data of the Patients.

Patients (n)
Mobilization regimen

Cisplatin-based þ G-CSF
Gemsitabin-based þ G-CSF
Plerixifor þ G-CSF
Median cell count
Median days (minemax)
Median days (minemax)

CD34 £ 106/kg
Neutrophil engraftment
Thrombocyte engraftment
Febrile neutropenic attack
Fever of unknown origin
Proven infections
Bacteremia
Pneumonia
Gastrointestinal infection
Urinary infections
Mucositis
Gastrointestinal toxicity
Renal toxicity
Hepatotoxicity
Transplant-related 100-day mortality (%)

Grade IeII
Grade IIIeIV
Grade IeII
Grade IIIeIV
Grade IeII
Grade IIIeIV
Grade IeII
Grade IIIeIV
Transplant-related mortality (TRM)

All patients

BEAM

Mx-Mel

101
90
4
6
9 (4e12)
11 (9e20)
12 (9e21)
51 (50.5)
39
12
6
2
2
2
37
31
35
8
11
2
10
1
3

60
55 (91.7)
2 (3.3)
3 (5)
9 (4e11)
10 (9e20)
12 (9e21)
29 (48.3)
22 (36.7)
6 (10)
3 (5)
1 (1.7)
1 (1.7)
1 (1.7)
22 (36.7)
19 (31.7)
22 (36.7)
5 (8.3)
8 (13.3)
1 (1.7)
6 (10)
1 (1.7)
2 (3.3)

41
35 (85.4)
3 (7.3)
3 (7.3)
9 (5e12)
12 (9e19)
12 (10e21)
22 (53.6)
17 (41.5)
6 (14.6)
3 (7.3)
1 (2.4)
1 (2.4)
1 (2.4)
15 (36.6)
12 (29.3)
13 (31.7)
3 (7.3)
3 (7.3)
1 (2.4)
4 (9.8)
0
1 (2.5)

p
0.57

0.11
<0.001
0.54
0.59
0.54
0.66

0.95
0.83
0.61
0.70
0.79

Note. Data are presented as n (%) unless otherwise indicated. BEAM ¼ BCNU, etoposide, ARA-C, and melphalan; G-CSF ¼ granulocyte
colony-stimulating factor; Mx-Mel ¼ mitoxantroneemelphalan. Data bold in font: A p-value less than 0.05 (typically  0.05) is statistically signiﬁcant.

gastrointestinal, and cardiac toxicity rates were
similar in both groups. However, the pulmonary
toxicity rate was 1.9% and 29.4% in the Mx-Mel and
BEAM groups, respectively ( p < 0.001). As a result of
this study, the Mx-Mel preparation regimen appears to be as effective as the BEAM regimen but
has better tolerability in terms of pulmonary toxicity
and can be used as an alternative option if necessary, depending on the patient’s comorbidity. In our
study, gastrointestinal, hepatic, and renal toxicity
was similar in both arms of regimens. We did not
observe signiﬁcant pulmonary toxicity in both
groups. Similar results were obtained in both
groups prepared for ASCT with similar demographic data. In contrast to this study, time to
neutrophil engraftment was shorter in the BEAM
arm; however, there is no statistical difference in
terms of severe infectious complications and febrile
neutropenic attacks. The evaluation of OS and PFS

in the 1-year period of our study seems more
optimal due to the signiﬁcant difference in followup durations between the two groups. There was
statistically no signiﬁcant difference between 1-year
OS and PFS between the two groups.
Okay et al. [11] reported the results of 53 patients
who underwent ASCT with the Mx-Mel conditioning regimen in 14 patients with R/R HL and 39 patients with NHL. Of these, 44 (86.2%) patients
achieved CR after peripheral stem cell infusion with
this conditioning regimen. The 2-year estimated OS
was 81.9% and PFS was 59.3%. In this mitoxantronebased study, we see that an effective conditioning
regimen has been put forward. Similarly, in another
study conducted by Oyan et al. [18], efﬁcacy was
evaluated in ASCT cases performed with Mx-Mel
conditioning regimen. In this Phase II study conducted with ASCT following the conditioning
regimen in a total of 40 patients diagnosed with R/R

Table 4. The Survival and Follow-Up Data.

1-year OS (%)
1-year PFS (%)
5-year OS (%)
5-year PFS (%)
Follow-up duration

Median months

Total patients

BEAM

Mx-Mel

p

97
95
69
63
24 (3e112)

96.6
95
69
61
44 (3e112)

97.5
95.1
75
74
14 (3e62)

0.68
0.88
0.70
0.81
<0.001

Note. BEAM ¼ BCNU, etoposide, ARA-C, and melphalan; Mx-Mel ¼ mitoxantroneemelphalan; OS ¼ overall survival; PFS ¼ progression-free survival.
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HL and NHL; 35 (90%) of the patients achieved CR
and the PFS rate was 71.7% at 4 years. TRM on Day
þ 100 was 2.5%. Similar to the 100-day TRM of this
mitoxantrone-based study in which signiﬁcant results were obtained with acceptable toxicity, mortality in our study was 2.9% with three patients. In
another study conducted by Tarella et al. [19],
effectiveness and hematologic/extrahematologic
toxicities of the Mx-Mel regimen were examined. A
total of 113 patients with lymphoma have undergone ASCT with Mx-Mel conditioning regimen and
successful results have been obtained with effective
treatment and reversible cardiotoxicity.
Engraftment failure, one of the most important
transplant-related complications, was not observed
in any of our cases; however, time to neutrophil
engraftment was longer in the Mx-Mel group than
in the other group. This result is parallel with the
examples in the literature [17]. The point to be
emphasized is that despite late neutrophil engraftment, signiﬁcant infectious complications, febrile
neutropenia attack, or TRM did not differ between
the two groups. Despite the length of engraftment
period, which can be considered as its most
important disadvantage, the fact that the important
infectious complications were not seen neither in
our study, nor in the literature, makes the Mx-Mel
regimen preferable and advantageous.
The search for an alternative to the BEAM regimen,
which is considered the standard for lymphoma and
ASCT, is based on carmustine toxicity. Several
studies have attempted to substitute bendamustine
thiotepa, fotemustine, lomustine, and mitoxantrone
instead of carmustine to demonstrate high efﬁcacy
and low toxicity [11,17,19]. It can be said that alternatives are preferable to avoid late toxicities such as
cardiovascular and pulmonary. There were no patients with signiﬁcant pulmonary and cardiotoxicity
in both our patient arms; however, due to retrospective examination, it was not possible to reach
further examination results such as pulmonary
function tests and echocardiography at predetermined intervals. Since there is no follow-up
period to evaluate the development of secondary
malignancy in our study and studies in the literature,
the advantage in this area cannot be evaluated;
however, it constitutes an important topic of
discussion.
As reported in literature [19], the most important
side effect associated with Mx-Mel is grade IIIeIV
mucositis. In our study, 12 (29.3%) patients had
grade IIIeIV mucositis; similarly, it is seen to be 31%
in the literature [19]. While hepatotoxicity and
increased liver enzymes were encountered in the
same study at a rate of 9%, it was found to be 9.8%

with four patients in our study. In this context, it can
be said that the Mx-Mel regimen will constitute an
alternative to BEAM regimen with low toxicity and
similar efﬁciency.
There were also limitations of this study. The most
important limitation was that patients were limited
to a small group when divided into subgroups.
Additionally, the fact that carmustine and its associated pulmonary and cardiac toxicities have not
been analyzed is another important limitation point.
The patients were evaluated retrospectively, and
Mx-Mel/BEAM regimen was used according to
treating physician’s preference and it caused unpredictable difﬁculties in comparisons. At this point,
a prospective study can be planned by dividing
patients into subgroups according to certain conditions. Due to the signiﬁcant difference in follow-up
durations between the two groups, the evaluation
does not appear to be optimal in terms of long-term
OS and PFS.
In conclusion, with this study, we show that the
Mx-Mel regimen has similar efﬁcacy and toxicity
compared with the BEAM regimen. Although time
to neutrophil engraftment was shorter in the BEAM
arm, it did not result as signiﬁcant transplantrelated complications between the two regimens.
Contrary to the example in the literature, no difference was found in platelet engraftment. The MxMel regimen is seen as a good alternative with low
toxicity and high efﬁcacy.
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